Molecular Neurodegeneration

Papers
(The median citation count of Molecular Neurodegeneration is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances527
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease396
PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease242
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease184
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis168
Initiation and propagation of α-synuclein aggregation in the nervous system146
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease100
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease100
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration98
Neuropathology and molecular diagnosis of Synucleinopathies95
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics94
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease92
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model88
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery86
TDP-43 Pathology in Alzheimer’s Disease85
New approaches to symptomatic treatments for Alzheimer’s disease84
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis83
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies83
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease81
Tauopathies: new perspectives and challenges80
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies80
Cellular and pathological heterogeneity of primary tauopathies79
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry78
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events78
Solving neurodegeneration: common mechanisms and strategies for new treatments77
NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma73
Post-infection cognitive impairments in a cohort of elderly patients with COVID-1972
Glycosphingolipids and neuroinflammation in Parkinson’s disease72
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns67
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers66
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice62
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology61
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination60
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease57
PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency56
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions56
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders55
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases55
Microbial involvement in Alzheimer disease development and progression55
Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment53
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients52
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives50
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment49
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia49
Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD48
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study48
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions47
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations46
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain46
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia44
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma44
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach44
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain42
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis42
Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease41
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology41
Alzheimer’s disease – the journey of a healthy brain into organ failure40
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease40
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice39
Identification of sixteen novel candidate genes for late onset Parkinson’s disease38
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments38
The role of inflammasomes in vascular cognitive impairment38
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored38
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE137
The informed road map to prevention of Alzheimer Disease: A call to arms37
Deciphering cellular transcriptional alterations in Alzheimer’s disease brains35
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease35
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease34
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease34
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application34
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target33
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease32
Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice32
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain32
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes31
α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment31
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration31
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis31
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM231
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models31
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes31
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model30
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease30
From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline30
Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease29
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction29
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis29
Sleep and circadian rhythms in Parkinson’s disease and preclinical models29
Basal lamina changes in neurodegenerative disorders28
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo27
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories27
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset26
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma26
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation26
BIN1 protein isoforms are differentially expressed in astrocytes, neurons, and microglia: neuronal and astrocyte BIN1 are implicated in tau pathology26
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy26
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications25
Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD25
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease25
Astrocyte-derived clusterin suppresses amyloid formation in vivo24
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers24
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques24
LRP1 is a neuronal receptor for α-synuclein uptake and spread24
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD24
Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice23
Parkinson’s disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging23
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains23
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia23
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia23
Peroxiredoxin 6 mediates protective function of astrocytes in Aβ proteostasis22
TREM2 dependent and independent functions of microglia in Alzheimer’s disease22
Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques21
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics21
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia21
Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration21
Integrated analysis of the aging brain transcriptome and proteome in tauopathy20
Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome20
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease19
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications19
Beyond association: successes and challenges in linking non-coding genetic variation to functional consequences that modulate Alzheimer’s disease risk19
Interleukin-6 deficiency exacerbates Huntington’s disease model phenotypes19
Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency19
Tau interactome and RNA binding proteins in neurodegenerative diseases19
Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro18
Pharmacological rescue of cognitive function in a mouse model of chemobrain18
Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures18
Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis18
The route of SARS-CoV-2 to brain infection: have we been barking up the wrong tree?18
A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease18
Aging-relevant human basal forebrain cholinergic neurons as a cell model for Alzheimer’s disease17
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD17
The era of cryptic exons: implications for ALS-FTD17
Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E17
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum17
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue17
Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing16
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease16
Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer’s disease in Tg2576 mice15
Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline15
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar15
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration15
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease15
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice15
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease15
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes14
Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer’s disease14
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease14
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma14
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE414
VCP suppresses proteopathic seeding in neurons14
Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy13
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy13
Activity of Alzheimer’s γ-secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity13
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms13
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease13
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy13
High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT313
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants12
The role of NURR1 in metabolic abnormalities of Parkinson’s disease12
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy12
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions12
Methods to investigate intrathecal adaptive immunity in neurodegeneration12
RETRACTED ARTICLE: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE412
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease12
When the infectious environment meets the AD brain12
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis12
Sex specific molecular networks and key drivers of Alzheimer’s disease12
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease12
Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes11
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination11
0.020345211029053